SEARCH

SEARCH BY CITATION

References

  • 1
    Tam CS, Heersche JN, Murray TM, Parsons JA. Parathyroid hormone stimulates the bone apposition rate independently of its resorptive action: differential effects of intermittent and continuous administration. Endocrinology. 1982; 110(2):50612.
  • 2
    Hock JM, Gera I. Effects of continuous and intermittent administration and inhibition of resorption on the anabolic response of bone to parathyroid hormone. J Bone Miner Res. 1992; 7(1):6572.
  • 3
    Dobnig H, Turner RT. The effects of programmed administration of human parathyroid hormone fragment (1-34) on bone histomorphometry and serum chemistry in rats. Endocrinology. 1997; 138(11):460712.
  • 4
    Shen V, Birchman R, Wu DD, Lindsay R. Skeletal effects of parathyroid hormone infusion in ovariectomized rats with or without estrogen repletion. J Bone Miner Res. 2000; 15(4):74060.
  • 5
    Sato M, Zheng GQ, Turner CH. Biosynthetic human parathyroid hormone (1-34) effects on bone quality in aged ovariectomized rats. Endocrinology. 1997; 138:43307.
  • 6
    Neer RM, Arnaud CD, Zanchetta JR, Prince R, Gaich GA, Reginster JY, Hodsman AB, Eriksen EF, Ish-Shalom S, Genant HK, Wang O, Mitlak BH. Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Eng J Med. 2001; 344:143441.
  • 7
    Body JJ, Gaich GA, Scheele WH, Kulkarni PM, Miller PD, Peretz A, Dore RK, Correa-Rotter R, Papaioannou A, Cumming DC, Hodsman AB. A randomized double-blind trial to compare the efficacy of teriparatide [recombinant human parathyroid hormone(1-34)] with alendronate in postmenopausal women with osteoporosis. J Clin Endocrinol Metab. 2002; 87:452835.
  • 8
    Fox J, Miller MA, Newman MK, Metcalf AF, Turner CH, Recker RR, Smith SY. Daily treatment of aged ovariectomized rats with human parathyroid hormone (1-84) reverses bone loss and enhances trabecular and cortical strength. Calcif Tissue Int. 2006; 79:26272.
  • 9
    Brixen KT, Christensen PM, Ejersted C, Langdahl BL. Teriparatide (biosynthetic human parathyroid hormone (1-34): a new paradigm in the treatment of osteoporosis. Basic Clin Pharmacol Toxicol. 2004; 94(6):26070.
  • 10
    Cosman F. Anabolic therapy for osteoporosis: parathyroid hormone. Curr Osteoporos Rep. 2005; 3(4):1439.
  • 11
    Koh AJ, Demiralp B, Neiva KG, Hooten J, Nohutcu RM, Shim H, Datta NS, Taichman RS, McCauley LK. Cells of the osteoclast lineage as mediators of the anabolic actions of parathyroid hormone in bone. Endocrinology. 2005; 146(11):458496.
  • 12
    Pierroz DD, Bonnet N, Baldock P, Ominsky MS, Stolina M. Kostenuik, Ferrari SL, Are osteoclasts needed for the bone anabolic response to parathyroid hormone? A study of intermittent parathyroid hormone with denosumab or alendronate in knock-in mice expressing humanized RANKL. J Biol Chem. 2010; 285(36):2816473.
  • 13
    Black DM, Greenspan SL, Ensrud KE, Palermo L, McGowan JA, Lang TF, Garnero P, Bouxsein ML, Bilezikian JP, Rosen CJ. PaTh Study Investigators. The effects of parathyroid hormone and alendronate alone or in combination in postmenopausal osteoporosis. N Engl J Med. 2003; 349(13):120715.
  • 14
    Abou-Samra AB, Juppner H, Force T, Freeman MW, Kong XF, Schipani E, Urena P, Richards J, Bonventre JV, Potts JT, Kronenberg HM, Segre GV. Expression cloning of a common receptor for parathyroid hormone and parathyroid hormone-related peptide from rat osteoblast-like cells: a single receptor stimulates accumulation of both cAMP and inositol triphosphates and increases intracellular free calcium. Proc Natl Acad Sci. 1992; 89(7):27326.
  • 15
    Nakashima T, Hayashi M, Fukunaga T, Kurata K, Oh-hura M, Feng JQ, Bonewald LF, Kodama T, Wutz A, Wagner EF, Penninger JM, Takayanagi H. Evidence for osteocyte regulation of bone homeostasis through RANKL expression. Nat Med. 2011; 17(10):12314.
  • 16
    Xiong J, Onal M, Jilka RL, Weinstein RS, Manolagas SC, O'Brien CA. Matrix-embedded cells control osteoclast function. Nat Med. 2011; 17(10):123541.
  • 17
    Rhee Y, Allen MR, Condon K, Lezcano V, Ronda AC, Galli C, Olives N, Passeri G, O'Brien CA, Bivi N, Plotkin LI, Bellido T. PTH receptor signaling in osteocytes governs periosteal bone formation and intracortical remodeling. J Bone Miner Res. 2011; 26(5):103546.
  • 18
    Qin L, Qiu P, Wang L, Li X, Swarthout JT, Soteropoulos P, Tolias P, Partridge NC. Gene expression profiles and transcription factors involved in parathyroid signaling in osteoblasts revealed by microarray and bioinformatics. J Biol Chem. 2003; 278(22):1972331.
  • 19
    Onyia JE, Helvering LM, Gelbert L, Wei T, Huang S, Chen P, Dow ER, Maran A, Zhang M, Lotinum S, Lin X, Halladay DL, Miles RR, Kulkarni NH, Ambrose EM, Ma YL, Frolik CA, Sato M, Bryant HU, Turner RT. Molecular profile of catabolic versus anabolic treatment regimens of parathyroid hormone (PTH) in rat bone: an analysis by DNA microarray. J Cell Biochem. 2005; 95(2):40318.
  • 20
    Li X, Hao L, Qin L, Tamasi J, Bergenstock M, Shapses S, Feyen JHM, Notterman DA, Partridge NC. Determination of dual effects of parathyroid hormone on skeletal gene expression in vivo by microarray and network analysis. J Biol Chem. 2007; 282:3308697.
  • 21
    Li X, Qin L, Bergenstock M, Bevelock LM, Novack DV, Partridge NC. Parathyroid hormone stimulates osteoblastic expression of MCP-1 to recruit and increase the fusion of preosteoclasts. J Biol Chem. 2007; 282:33098106.
  • 22
    Paavola CD, Hemmerich S, Grunberger D, Polsky I, Bloom A, Freedman R, Mulkins M, Bhakta S, McCarley D, Wiesent L, Wong B, Jarnagin K, Handel TM. Monomeric monocyte chemoattractant protein-1 (MCP-1) binds and activates the MCP-1 receptor CCR2B. J Biol Chem. 1998; 273(50):3315765.
  • 23
    Lu B, Rutledge BJ, Gu L, Fiorillo J, Lukacs NW, Kunkel SL, North R, Gerard C, Rollins BJ. Abnormalities in monocyte recruitment and cytokine expression in monocyte chemoattractant protein-1 deficient mice. J Exp Med. 1998; 187(4):6018.
  • 24
    Takayanagi H. Osteoimmunology: shared mechanisms and crosstalk between the immune and bone systems. Nat Rev Immunol. 2007; 7(4):292304.
  • 25
    Graves DT, Jiang Y, Valente AJ. Regulated expression of MCP-1 by osteoblastic cells in vitro and in vivo. Histol Histopathol. 1999; 14(4):134754.
  • 26
    Boring L, Gosling J, Chensue SW, Kunkel SL, Farese RV, Broxmeyer HE, Charo IF. Impaired monocyte migration and reduced type 1 (Th1) cytokine responses in C-C chemokine receptor 2 knockout mice. J Clin Invest. 1997; 100(10):225261.
  • 27
    Smith EA, Hanson NA, Crawford DT, Brown TA, Buckbinder L. CCR2 receptor signaling is involved in bone mass regulation and mediates the response to anabolic but not catabolic regimens of PTH(1–34). J Bone Miner Res. 2008; 23:S280.
  • 28
    Binder NB, Niederreiter B, Hoffman O, Stange R, Pap T, Stulnig TM, Mack M, Erben RG, Smolen JS, Redlich K. Estrogen-dependent and C-C chemokine receptor-2-dependent pathways determine osteoclast behavior in osteoporosis. Nat Med. 2009; 15(4):41724.
  • 29
    Charo IF, Ransohoff RM. The many roles of chemokines and chemokine receptors in inflammation. N Engl J Med. 2006; 354(6):61021.
  • 30
    Deshmane SL, Kremiev S, Amini S, Sawaya BE. Monocyte chemoattractant protein-1 (MCP-1): an overview. J Interferon Cytokine Res. 2009; 29(6):31326.
  • 31
    Bouxsein ML, Boyd SK, Christiansen BA, Guldberg RE, Jepsen KJ, Müller R. Guidelines for assessment of bone microstructure in rodents using micro-computed tomography. J Bone Miner Res. 2010; 25:146886.
  • 32
    Parfitt AM, Drezner MK, Glorieux FH, Kanis JA, Malluche H, Meunier PJ, Ott SM, Recker RR. Bone histomorphometry: standardization of nomenclature, symbols and units: report of the ASBMR Histomorphometry Nomenclature Committee. J Bone Miner Res. 1987; 2(6):595610.
  • 33
    Damoiseaux JGMC, Döpp EA, Calame W, Chao D, MacPherson GG, Dijkstra CD. Rat macrophage lysosomal membrane antigen recognized by monoclonal antibody ED-1. Immunology. 1994; 83(1):1407.
  • 34
    Somerville JN, Aspden RM, Armour KE, Armour KJ, Reid DM. Growth of C57Bl/6 mice and mechanical properties of cortical bone from the tibia. Calcif Tissue Int. 2004; 74(5):46975.
  • 35
    Sukumar D, Partridge NC, Wang X, Shapses SA. The high serum monocyte chemoattractant protein-1 in obesity is influenced by high serum parathyroid hormone and not adiposity. J Clin Endocrinol Metab. 2011; 96(6):18528.
  • 36
    Sartipy P, Loskutoff DJ. Monocyte chemoattractant protein-1 in obesity and insulin resistance. Proc Natl Acad Sci. 2003; 100(12):726570.
  • 37
    Störk S, Baumann K, von Schacky C, Angerer P. The effect of 17β-estradiol on MCP-1 serum levels in postmenopausal women. Cardiovasc Res. 2002; 53(3):6429.
  • 38
    Arici A, Senturk LM, Seli E, Bahtiyar MO, Kim G. Regulation of monocyte chemoattractant protein 1 expression in human endometrial stromal cells by estrogen and progesterone. Biol Reprod. 1999; 61(1):8590.
  • 39
    Pervin S, Singh R, Rosenfeld ME, Navab M, Chaudhuri G, Nathan L. Estradiol suppresses MCP-1 expression in vivo: implications for atherosclerosis. Arterioscler Thromb Vasc Biol. 1998; 18(10):157582.
  • 40
    Volejnikova S, Laskari M, Marks SC, Graves DT. Monocyte recruitment and expression of monocyte chemoattractant protein-1 are developmentally regulated in remodeling bone in the mouse. Am J Pathol. 1997; 150(5):171121.
  • 41
    Lisignoli G, Toneguzzi S, Grassi F, Piacentini A, Tschon M, Cristino S, Gualtieri G, Facchini A. Different chemokines are expressed in human arthritic bone biopsies: IFN-g and IL-6 differentially modulate IL-8, MCP-1 and RANTES production by arthritic osteoblasts. Cytokine. 2002; 20(5):2318.
  • 42
    Kim MS, Day CJ, Morrison NA. MCP-1 is induced by receptor activator of nuclear factor-kβ ligand, promotes human osteoclast fusion, and rescues granulocyte macrophage colony-stimulating factor suppression of osteoclast formation. J Biol Chem. 2005; 280(16):161639.
  • 43
    Miyamoto K, Ninomiya K, Sonoda K-H, Miyauchi Y, Hoshi H, Iwasaki R, Miyamoto H, Yosida S, Sato Y, Morioka H, Chiba K, Egashira K, Suda T, Toyama Y, Miyamoto T. MCP-1 expression by osteoclasts stimulates osteoclastogenesis in an autocrine/paracrine manner. Biochem Biophys Res Commun. 2009; 383(3):3737.
  • 44
    Huang JC, Sakata T, Pfleger LL, Bencsik M, Halloran BP, Bikle DD, Nissenson RA. PTH differentially regulates expression of RANKL and OPG. J Bone Miner Res. 2004; 19(2):23544.
  • 45
    Weir EC, Horowitz MC, Baron R, Centrella M, Kacinski BM, Insogna KL. Macrophage colony-stimulating factor release and receptor expression in bone cells. J Bone Miner Res. 1993; 8(12):150718.
  • 46
    Kyriakides TR, Foster MJ, Keeney GE, Tsai A, Giachelli CM, Clark-Lewis I, Rollins BJ, Bornstein P. The CC chemokine ligand, CCL2/MCP-1, participates in macrophage fusion and foreign body giant cell formation. Am J Pathol. 2004; 165(6):215766.
  • 47
    Boyle WJ, Simone WS, Lacey DL. Osteoclast differentiation and activation. Nature. 2003; 423(6937):33742.
  • 48
    Posner LJ, Miligkos T, Gilles JA, Carnes DL, Taddeo DR, Graves DT. Monocyte chemoattractant protein-1 induces monocyte recruitment that is associated with an increase in numbers of osteoblasts. Bone. 1997; 21(4):3217.